Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment

Journal of Rheumatology

Volumn 41, Issue SUPPL. 91, 2014, Pages 78-82

  Cantini, Fabrizio ^a   Prignano, Francesca ^b   Goletti, Delia ^c  

^a HOSPITAL OF PRATO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Translational Research Unit Department of Epidemiology and Preclinical Research ^*  (Italy)

Author keywords

Active tuberculosis; Anti tumor necrosis factor; Biologics; Disease activity; Disease flare

Indexed keywords

ABATACEPT; ADALIMUMAB; ANALGESIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETHAMBUTOL; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZINAMIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUBERCULOSTATIC AGENT;

ANKYLOSING SPONDYLITIS; ARTICLE; BACTERIAL PHENOMENA AND FUNCTIONS; BIOLOGICAL THERAPY; CHEMOPROPHYLAXIS; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MANAGEMENT; HUMAN; INFECTION RISK; MEDICATION THERAPY MANAGEMENT; PATIENT CARE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RECURRENCE RISK; RELAPSE; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; RISK FACTOR; TOPICAL TREATMENT; TREATMENT WITHDRAWAL; TUBERCULOSIS; TUBERCULOSIS CONTROL; TUBERCULOSIS REACTIVATION; COMPLICATION; RHEUMATIC DISEASES;

ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; BIOLOGICAL PRODUCTS; HUMANS; PSORIASIS; RHEUMATIC DISEASES; TUBERCULOSIS;

EID: 84899787892     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140106     Document Type: Article

References (49)

1. World Health Organization Global Tuberculosis Report 2012. WHO Library Cataloguing-in-Publication Data. Geneva: Information Resource Centre HTM/STB World Health Organization; 2012.
2. Zuniga J, Torres-Garcia D, Santos-Mendoza T, Rodriguez-Reyna TS, Granados J, Yunis EJ. Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol 2012;2012:193923.
3. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010;59 RR-5:1-25.
4. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 Suppl 2:1-70.
5. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
6. Doherty SD, van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis Foundation. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008;59:209-17.
7. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72. (Pubitemid 40852885)
8. Gomez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61. (Pubitemid 46932080)
9. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731-40. (Pubitemid 19082507)
10. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989;143:2894-9. (Pubitemid 19281835)
11. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 1991;49:380-7.
12. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92. (Pubitemid 40994319)
13. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:2368-76. (Pubitemid 44204996)
14. Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009;22:403-9.
15. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006;43:717-22. (Pubitemid 44330734)
16. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011;70:2148-51.
17. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32.
18. Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011;13:R75.
19. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology 2011;50:222-9.
20. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168:844-54
21. Balato N, Di Costanzo L, Ayala F, Balato A, Sanduzzi A, Bocchino M. Psoriatic disease and tuberculosis nowadays. Clin Dev Immunol 2012;2012:747204.
22. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300-4.
23. Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2006;65:1661-3. (Pubitemid 44799684)
24. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11.
25. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791. (Pubitemid 36886422)
26. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
27. Fonseca JE, Lucas H, Canhao H, Duarte R, Santos MJ, Villar M, et al. Recommendations for the diagnosis and treatment of latent and active tuberculosis in patients with inflammatory joint diseases treated with tumour necrosis factor alpha inhibitors. Acta Reumatol Port 2006;31:237-45.
28. Valesini G, Montecucco C, Cutolo M. Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 2006;24:413-23. (Pubitemid 44363543)
29. Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, et al. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 2011;29 Suppl 66:S28-41.
30. Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620-2.
31. Kavanagh PM, Gilmartin JJ, O'Donnell J, O'Flanagan D. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee. Ir Med J 2008;101:6-7.
32. Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K. Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 2009;63:329-34.
33. Solovic I, Sester M, Gomez-Reino JJ, Ehlers S, Milburn HJ, Kampmann B, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
34. Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 2012;59:C4480.
35. Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 2012;39:1583-602.
36. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019.
37. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94.
38. Denis B, Lefort A, Flipo RM, Tubach F, Lemann M, Ravaud P, et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-a antagonist therapy: safe re-initiation of TNF-a blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 2008;14:183-6.
39. Treatment of tuberculosis: guidelines. 4th ed. Geneva: World Health Organization; 2010.
40. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb Mortal WklyRep 2004;53:683-6.
41. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26. (Pubitemid 43235123)
42. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013;72:37-42.
43. Xanthouli P, Sailer S, Fiehn C. Rituximab (RTX) as an alternative to TNF-alpha antagonists in patients with rheumatoid arthritis and high risk of severe infections: a systematic analysis of the experience in one center. Open Rheumatol J 2012;6:286-9.
44. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-40.
45. Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48.
46. Van Gestel AM, Haagsma CJ, Van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50. (Pubitemid 28465539)
47. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
48. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011;63:1543-51.
49. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)